Brain Imaging of Amyloid Plaques in Aging and Memory Disorders
Uses PET brain scans with a tracer to track amyloid plaques over time.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Imaging of Brain Amyloid Plaques in the Aging Population
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 8,000 people, planned
- Started
- Apr 2008
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- Pittsburgh Compound B (C-11 PiB)
- F-18 FDG
- Tau (18-F-AV-1451)
- Record updated
- 23 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 30 to 100 who have had, or will have, a brain and memory check in a Mayo Clinic aging or dementia program. It uses brain scans to follow amyloid changes over time.
- Age
- 30 to 100 years
- Sex
- All sexes can join.
Main reasons for not taking part
- Cannot lie still for 10 minutes
- Pregnant, or cannot stop breast feeding for 24 hours at the time of scanning
- Claustrophobic and cannot tolerate the scans
- Standard MRI safety exclusions, such as metallic foreign bodies or a pacemaker
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 30-100
- Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics
Who cannot take part
- Subjects unable to lie down without moving for 10 minutes
- Women who are pregnant or cannot stop breast feeding for 24 hours at the time of scanning
- Claustrophobic patients unable to tolerate the scans
- Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 100 years old?
Where in United States
- Mayo ClinicRochester, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.
The group in the trial
- PiB PET, FDG PET, Tau PETTreatment being tested
Treatment: Pittsburgh Compound B (C-11 PiB), F-18 FDG, and Tau (18-F-AV-1451)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia
- Plain-language title
- Brain Imaging of Amyloid Plaques in Aging and Memory DisordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT00950430, who can take part
- Record updated
- 23 June 2026